Please use this identifier to cite or link to this item: https://doi.org/10.1097/01.mot.0000183244.59344.dc
Title: The use of alemtuzumab (Campath 1H) in organ transplant recipients
Authors: Calne, S.R. 
Keywords: Alemtuzumab
CD52
Immunosuppression
Induction therapy
Lymphocytes
Organ transplantation
Prope tolerance
Issue Date: Dec-2005
Source: Calne, S.R. (2005-12). The use of alemtuzumab (Campath 1H) in organ transplant recipients. Current Opinion in Organ Transplantation 10 (4) : 261-264. ScholarBank@NUS Repository. https://doi.org/10.1097/01.mot.0000183244.59344.dc
Abstract: Purpose of review: Alemtuzumab (Campath 1H) is a powerful lympholytic monoclonal antibody, which is only effective against human lymphocytes. It has been used in a number of autoimmune diseases and has had especially good results in the management of chronic lymphatic leukemia. Recent findings: Recent studies and clinical trials have defined optimal modes of administration of the antibody. The principle is to give one or two doses to the patient in the perioperative part of the organ transplant as a preemptive strike. T and B lymphocytes are banished from the circulation for approximately 1 month. Advantage is taken of this period of relative immuno-incompetence to establish maintenance immunosuppression at a very low dose. Half the normal dose of one calcineurin inhibitor is sufficient to maintain good organ function without the need for conventional immunosuppression. In particular corticosteroids can be avoided in most patients. This contributes to a good quality of life. The protocol is much cheaper than conventional immunosuppression and long-term follow-up has given encouraging results. Summary: A monoclonal antibody that targets the lymphocyte surface antigen CD52 was recently developed for use in humans. In clinical trials the antibody was shown to have striking effects on lymphocytes being responsible for a drastic reduction in lymphocyte numbers within the very first few hours after infusion. Lymphocyte depletion is maintained for several weeks despite only two doses of the antibody being administered. This affords maintenance immunosuppressive regimen in which significantly less drugs are used, which results in better tolerability and less costs. © 2005 Lippincott Williams & Wilkins.
Source Title: Current Opinion in Organ Transplantation
URI: http://scholarbank.nus.edu.sg/handle/10635/130648
ISSN: 10872418
DOI: 10.1097/01.mot.0000183244.59344.dc
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

2
checked on Feb 27, 2018

Page view(s)

10
checked on Feb 25, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.